(Q38682453)

5 September 2017

title

Autophagy, a double-edged sword in anti-angiogenesis therapy (English)

1 reference

5 September 2017

0 references

Jiatao Liu

1

1 reference

5 September 2017

Lulu Fan

series ordinal

2

1 reference

5 September 2017

Hua Wang

series ordinal

3

1 reference

5 September 2017

Guoping Sun

series ordinal

4

1 reference

5 September 2017

publication date

29 December 2015

1 reference

5 September 2017

1 reference

5 September 2017

volume

33

1 reference

5 September 2017

issue

1

1 reference

5 September 2017

page(s)

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-015-0721-9

5 September 2017

exact match

0 references

cites work

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Changes in blood vessel maturation in the fibrous cap of the tumor rim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Eating the endoplasmic reticulum: quality control by autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy in the Pathogenesis of Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Induction of autophagy and inhibition of tumorigenesis by beclin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Tissue-specific Autophagy Alterations and Increased Tumorigenesis in Mice Deficient in Atg4C/Autophagin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Role of autophagy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Lung cancer neovascularisation: Cellular and molecular interaction between endothelial and lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Angiogenesis as a strategic target for ovarian cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Angiogenesis in life, disease and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Regulation of angiogenesis by hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Antiangiogenic therapy and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1α signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Nicotine promotes proliferation of human nasopharyngeal carcinoma cells by regulating α7AChR, ERK, HIF-1α and VEGF/PEDF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

The meaning, measurement and modification of hypoxia in the laboratory and the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

HIF-1: a key mediator in hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Targeting hypoxia in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Biology of hypoxia-inducible factor-2alpha in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

The correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients' clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy is required during cycling hypoxia to lower production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

HIF-1α-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-induced autophagy promotes human prostate stromal cells survival and ER-stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

The role of autophagy in cancer development and response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Signaling unmasked: Autophagy and catalase promote programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Mutational landscape of the essential autophagy gene BECN1 in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagic cell death induced by 5-FU in Bax or PUMA deficient human colon cancer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

The role of autophagy during the early neonatal starvation period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Role of autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Anti- and pro-tumor functions of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy contributes to resistance of tumor cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0721-9

Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer

21 January 2018

1 reference

12 December 2020

Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.

1 reference

12 December 2020

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

1 reference

12 December 2020

Autophagy is a therapeutic target in anticancer drug resistance.

1 reference

12 December 2020

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells

1 reference

12 December 2020

Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma

1 reference

12 December 2020

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

1 reference

12 December 2020

Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells.

1 reference

12 December 2020

Erythropoietin combined with granulocyte colony‑stimulating factor enhances MMP-2 expression in mesenchymal stem cells and promotes cell migration.

1 reference

12 December 2020

Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer

1 reference

12 December 2020

Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

1 reference

12 December 2020

Autophagy in Human Health and Disease

1 reference

12 December 2020

Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells

1 reference

12 December 2020

Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.

1 reference

12 December 2020

10.1007/S12032-015-0721-9

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1025192125

0 references

1 reference